Company intelligence / Profile preview

Sensible Medical Innovations

Ownership: Private
Development stage: Phase 2

Overview

The ReDS system provides accurate pulmonary congestion assessment for heart failure patients. A recent trial (ReDS-SAFE HF) evaluated ReDS before and after discharge in patients with acute decompensated heart failure[1][3].

Therapeutic areas: CardiovascularNephrology
Modalities: Non-invasive monitoring technology
Industry: Physiological Monitoring

Drug pipeline

2 assets

dexmedetomidine

Phase 2

Indications: Post-operative pain, Cancer breakthrough pain, Chronic lower back pain

1 more asset in the full pipeline.

Request access →

Partnerships

Heart Beat Medical (UAE partnership)[9]

Beyond the preview

Go deeper on Sensible Medical Innovations.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sensible Medical Innovations.

Explore the full profile